298 related articles for article (PubMed ID: 25051119)
41. 5-Aza-2'-deoxycytidine (decitabine) can relieve p21WAF1 repression in human acute myeloid leukemia by a mechanism involving release of histone deacetylase 1 (HDAC1) without requiring p21WAF1 promoter demethylation.
Scott SA; Dong WF; Ichinohasama R; Hirsch C; Sheridan D; Sanche SE; Geyer CR; Decoteau JF
Leuk Res; 2006 Jan; 30(1):69-76. PubMed ID: 16043219
[TBL] [Abstract][Full Text] [Related]
42. Epigenetic Combination Therapy for Children With Secondary Myelodysplastic Syndrome (MDS)/Acute Myeloid Leukemia (AML) and Concurrent Solid Tumor Relapse.
Glasser CL; Lee A; Eslin D; Marks L; Modak S; Glade Bender JL
J Pediatr Hematol Oncol; 2017 Oct; 39(7):560-564. PubMed ID: 28562519
[TBL] [Abstract][Full Text] [Related]
43. Decitabine.
Hackanson B; Daskalakis M
Recent Results Cancer Res; 2014; 201():269-97. PubMed ID: 24756800
[TBL] [Abstract][Full Text] [Related]
44. Platelet doubling after the first azacitidine cycle is a promising predictor for response in myelodysplastic syndromes (MDS), chronic myelomonocytic leukaemia (CMML) and acute myeloid leukaemia (AML) patients in the Dutch azacitidine compassionate named patient programme.
van der Helm LH; Alhan C; Wijermans PW; van Marwijk Kooy M; Schaafsma R; Biemond BJ; Beeker A; Hoogendoorn M; van Rees BP; de Weerdt O; Wegman J; Libourel WJ; Luykx-de Bakker SA; Minnema MC; Brouwer RE; Croon-de Boer F; Eefting M; Jie KS; van de Loosdrecht AA; Koedam J; Veeger NJ; Vellenga E; Huls G
Br J Haematol; 2011 Dec; 155(5):599-606. PubMed ID: 21981697
[TBL] [Abstract][Full Text] [Related]
45. Simultaneous inhibition of DNA methyltransferase and histone deacetylase induces p53-independent apoptosis via down-regulation of Mcl-1 in acute myelogenous leukemia cells.
Nishioka C; Ikezoe T; Yang J; Udaka K; Yokoyama A
Leuk Res; 2011 Jul; 35(7):932-9. PubMed ID: 21550660
[TBL] [Abstract][Full Text] [Related]
46. Current status of epigenetic treatment in myelodysplastic syndromes.
Kuendgen A; Lübbert M
Ann Hematol; 2008 Aug; 87(8):601-11. PubMed ID: 18392623
[TBL] [Abstract][Full Text] [Related]
47. Low serum vitamin D levels are associated with shorter survival after first-line azacitidine treatment in patients with myelodysplastic syndrome and secondary oligoblastic acute myeloid leukemia.
Radujkovic A; Schnitzler P; Ho AD; Dreger P; Luft T
Clin Nutr; 2017 Apr; 36(2):542-551. PubMed ID: 26899917
[TBL] [Abstract][Full Text] [Related]
48. Epigenetic dysregulation of ID4 predicts disease progression and treatment outcome in myeloid malignancies.
Zhou JD; Zhang TJ; Li XX; Ma JC; Guo H; Wen XM; Zhang W; Yang L; Yan Y; Lin J; Qian J
J Cell Mol Med; 2017 Aug; 21(8):1468-1481. PubMed ID: 28452111
[TBL] [Abstract][Full Text] [Related]
49. Phase I/II trial of the combination of midostaurin (PKC412) and 5-azacytidine for patients with acute myeloid leukemia and myelodysplastic syndrome.
Strati P; Kantarjian H; Ravandi F; Nazha A; Borthakur G; Daver N; Kadia T; Estrov Z; Garcia-Manero G; Konopleva M; Rajkhowa T; Durand M; Andreeff M; Levis M; Cortes J
Am J Hematol; 2015 Apr; 90(4):276-81. PubMed ID: 25530214
[TBL] [Abstract][Full Text] [Related]
50. Clonogenic acute myelogenous leukemia cells are heterogeneous with regard to regulation of differentiation and effect of epigenetic pharmacological targeting.
Ryningen A; Stapnes C; Bruserud Ø
Leuk Res; 2007 Sep; 31(9):1303-13. PubMed ID: 17416413
[TBL] [Abstract][Full Text] [Related]
51. Panobinostat in lymphoid and myeloid malignancies.
Khot A; Dickinson M; Prince HM
Expert Opin Investig Drugs; 2013 Sep; 22(9):1211-23. PubMed ID: 23826641
[TBL] [Abstract][Full Text] [Related]
52. Epigenetic regulation of PRAME in acute myeloid leukemia is different compared to CD34+ cells from healthy donors: effect of 5-AZA treatment.
Gutierrez-Cosío S; de la Rica L; Ballestar E; Santamaría C; Sánchez-Abarca LI; Caballero-Velazquez T; Blanco B; Calderón C; Herrero-Sánchez C; Carrancio S; Ciudad L; Cañizo C; San Miguel JF; Pérez-Simón JA
Leuk Res; 2012 Jul; 36(7):895-9. PubMed ID: 22503131
[TBL] [Abstract][Full Text] [Related]
53. [Epigenetic therapy in myelodysplastic syndromes].
Maki K; Mitani K
Rinsho Ketsueki; 2011 Jul; 52(7):438-46. PubMed ID: 21821974
[No Abstract] [Full Text] [Related]
54. Clinical results with the DNA hypomethylating agent 5-aza-2'-deoxycytidine (decitabine) in patients with myelodysplastic syndromes: an update.
Joeckel TE; Lübbert M
Semin Hematol; 2012 Oct; 49(4):330-41. PubMed ID: 23079063
[TBL] [Abstract][Full Text] [Related]
55. Predicting infections in high-risk patients with myelodysplastic syndrome/acute myeloid leukemia treated with azacitidine: a retrospective multicenter study.
Merkel D; Filanovsky K; Gafter-Gvili A; Vidal L; Aviv A; Gatt ME; Silbershatz I; Herishanu Y; Arad A; Tadmor T; Dally N; Nemets A; Rouvio O; Ronson A; Herzog-Tzarfati K; Akria L; Braester A; Hellmann I; Yeganeh S; Nagler A; Leiba R; Mittelman M; Ofran Y
Am J Hematol; 2013 Feb; 88(2):130-4. PubMed ID: 23345248
[TBL] [Abstract][Full Text] [Related]
56. Absence of aberrant myeloid progenitors by flow cytometry is associated with favorable response to azacitidine in higher risk myelodysplastic syndromes.
Alhan C; Westers TM; van der Helm LH; Eeltink C; Huls G; Witte BI; Buchi F; Santini V; Ossenkoppele GJ; van de Loosdrecht AA
Cytometry B Clin Cytom; 2014 May; 86(3):207-15. PubMed ID: 24474614
[TBL] [Abstract][Full Text] [Related]
57. Efficacy of epigenetic agents for older patients with acute myeloid leukemia and myelodysplastic syndrome in randomized controlled trials: a systematic review and network meta-analysis.
Oh S; Kim E
Clin Exp Med; 2023 Oct; 23(6):2705-2714. PubMed ID: 36964818
[TBL] [Abstract][Full Text] [Related]
58. Phase 2 clinical trial of 5-azacitidine, valproic acid, and all-trans retinoic acid in patients with high-risk acute myeloid leukemia or myelodysplastic syndrome.
Raffoux E; Cras A; Recher C; Boëlle PY; de Labarthe A; Turlure P; Marolleau JP; Reman O; Gardin C; Victor M; Maury S; Rousselot P; Malfuson JV; Maarek O; Daniel MT; Fenaux P; Degos L; Chomienne C; Chevret S; Dombret H
Oncotarget; 2010 May; 1(1):34-42. PubMed ID: 21293051
[TBL] [Abstract][Full Text] [Related]
59. Influence of total genomic alteration and chromosomal fragmentation on response to a combination of azacitidine and lenalidomide in a cohort of patients with very high risk MDS.
Ganster C; Shirneshan K; Salinas-Riester G; Braulke F; Schanz J; Platzbecker U; Haase D
Leuk Res; 2015 Oct; 39(10):1079-87. PubMed ID: 26278198
[TBL] [Abstract][Full Text] [Related]
60. Pharmacokinetics and Pharmacodynamics with Extended Dosing of CC-486 in Patients with Hematologic Malignancies.
Laille E; Shi T; Garcia-Manero G; Cogle CR; Gore SD; Hetzer J; Kumar K; Skikne B; MacBeth KJ
PLoS One; 2015; 10(8):e0135520. PubMed ID: 26296092
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
